Wedbush Comments on Werewolf Therapeutics, Inc.’s Q3 2023 Earnings (NASDAQ:HOWL)

Posted by Defense World Staff on Aug 28th, 2023

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Free Report) – Stock analysts at Wedbush issued their Q3 2023 earnings per share (EPS) estimates for shares of Werewolf Therapeutics in a research report issued on Wednesday, August 23rd. Wedbush analyst R. Driscoll expects that the company will earn ($0.40) per share for the quarter. Wedbush currently has a “Outperform” rating and a $9.00 target price on the stock. The consensus estimate for Werewolf Therapeutics’ current full-year earnings is ($1.16) per share. Wedbush also issued estimates for Werewolf Therapeutics’ Q4 2023 earnings at ($0.41) EPS, FY2023 earnings at ($1.31) EPS, FY2024 earnings at ($1.46) EPS, FY2025 earnings at ($1.24) EPS, FY2026 earnings at ($1.21) EPS and FY2027 earnings at ($1.70) EPS.

Several other analysts also recently issued reports on HOWL. Bank of America increased their price target on Werewolf Therapeutics from $9.00 to $10.00 in a report on Friday, May 12th. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Werewolf Therapeutics in a report on Thursday, August 10th.

Check Out Our Latest Report on Werewolf Therapeutics

Werewolf Therapeutics Stock Down 6.4 %

HOWL stock opened at $3.06 on Monday. Werewolf Therapeutics has a 52 week low of $1.39 and a 52 week high of $7.51. The company has a debt-to-equity ratio of 0.33, a quick ratio of 9.82 and a current ratio of 9.82. The business has a fifty day simple moving average of $2.91 and a 200-day simple moving average of $2.83.

Hedge Funds Weigh In On Werewolf Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Chicago Partners Investment Group LLC purchased a new position in Werewolf Therapeutics in the 4th quarter valued at about $41,000. Cubist Systematic Strategies LLC purchased a new position in Werewolf Therapeutics in the 2nd quarter valued at about $54,000. Renaissance Technologies LLC purchased a new position in Werewolf Therapeutics in the 2nd quarter valued at about $69,000. Bailard Inc. purchased a new position in Werewolf Therapeutics in the 1st quarter valued at about $47,000. Finally, Jane Street Group LLC bought a new position in shares of Werewolf Therapeutics during the fourth quarter worth about $45,000. 67.44% of the stock is owned by hedge funds and other institutional investors.

About Werewolf Therapeutics

(Get Free Report)

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.